Core Viewpoint - Trinity Biotech plc is welcoming a proposal from its largest investor, Perceptive Advisors, to convert a portion of its outstanding debt into equity, which is seen as a strategic initiative to strengthen the company's balance sheet and enhance financial flexibility [1][2]. Company Overview - Trinity Biotech is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors [5]. - The company develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical laboratory segments, with recent expansion into the wearable biosensor industry through the acquisition of Waveform Technologies Inc. [5]. - Products include diagnostics for infectious diseases and quantification of Haemoglobin A1c and other chemistry parameters in various blood samples [5]. Investor Relations - Perceptive Advisors, a leading life sciences investment firm with approximately $8 billion in assets, has been a supportive partner during Trinity Biotech's transformation [2][7]. - The proposed equitization program aims to align the interests of all stakeholders, including shareholders, and is expected to facilitate discussions that are mutually beneficial [3][2].